All > Heart Failure With Preserved Ejection Fraction > Congestive Heart Failure

Empagliflozin 25 MG + Liraglutide 1.8 MG for Type 2 Diabetes

Renal Physiology Laboratory, Toronto, Canada
Type 2 DiabetesEmpagliflozin 25 MG + Liraglutide 1.8 MG - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial studies how two diabetes treatments affect heart health in people with type 2 diabetes without heart failure.

Eligible Conditions
  • Type 2 Diabetes

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase 2

Similar Trials

1
Evorpacept (ALX148) + Enfortumab Vedotin
1
HC-7366
1
JNJ-64264681

Study Objectives

1 Primary · 7 Secondary · Reporting Duration: Outcome will be measured at 2 time points: monotherapy (6 weeks) and combination therapy (12 weeks)

Week 12
Arterial stiffness
Week 12
Body weight
Week 12
Glomerular Filtration Rate
Week 12
Urinary EGF,FGF2,Eotaxin,TGFa,G-CSF,Flt-3L,GM-CSF,Fractalkine,IFNa2,IFNy,GRO,IL10,MCP-3,IL-12P40,MDC,IL-12P70,PDGF-AA,IL-13,PDGF-BB,IL-15,sCD40L,IL-17A,IL-1RA,IL1a,IL9,IL1B,IL2,IL3,IL4,IL5,IL6,IL7,IL8,IL10,MCP-1,MIP-1a,MIP-1B,RANTES,TNFalpha,TNFB,VEGF
Urinary concentration of the renin-angiotensin aldosterone system (RAAS) markers
Week 12
Systemic vascular resistance
Week 12
Systolic blood pressure
up to 12 weeks
Proximal tubular natriuresis

Trial Safety

Phase-Based Safety

2 of 3
This is further along than 68% of similar trials

Similar Trials

1
Evorpacept (ALX148) + Enfortumab Vedotin
1
HC-7366
1
JNJ-64264681

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.

Trial Design

2 Treatment Groups

Liraglutide
1 of 2
Empagliflozin
1 of 2

Experimental Treatment

36 Total Participants · 2 Treatment Groups

Primary Treatment: Empagliflozin 25 MG + Liraglutide 1.8 MG · No Placebo Group · Phase 2

LiraglutideExperimental Group · 2 Interventions: Liraglutide 1.8 MG + Empagliflozin 25 MG, Empagliflozin 25 MG + Liraglutide 1.8 MG · Intervention Types: Drug, Drug
EmpagliflozinExperimental Group · 2 Interventions: Liraglutide 1.8 MG + Empagliflozin 25 MG, Empagliflozin 25 MG + Liraglutide 1.8 MG · Intervention Types: Drug, Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: outcome will be measured at 2 time points: monotherapy (6 weeks) and combination therapy (12 weeks)

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor
1,395 Previous Clinical Trials
474,325 Total Patients Enrolled
David ZI Cherney, MD PhD FRCPCPrincipal InvestigatorUniversity Health Network, Toronto General Hospital
1 Previous Clinical Trials
50 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 8 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
References

Frequently Asked Questions

Is this experiment currently admitting participants?

"The information on clinicaltrials.gov confirms that this medical trial is not currently enrolling patients. Initially posted on January 24th 2019, it was last updated September 1st 2020 and no longer seeks participants; however, 2261 other studies are still actively recruiting at the moment." - Anonymous Online Contributor

Unverified Answer

To what medical conditions is Empagliflozin 25 MG + Liraglutide 1.8 MG prescribed?

"Empagliflozin 25 MG + Liraglutide 1.8MG is frequently utilized for hospitalizations, but can also be used therapeutically to combat diet-related issues, inadequate control when relying upon a single medication treatment plan, and cardiovascular diseases." - Anonymous Online Contributor

Unverified Answer

To what extent does the combination of Empagliflozin 25 MG + Liraglutide 1.8 MG pose a risk to patients?

"Due to the lack of clinical data that has been gathered on efficacy, Empagliflozin 25 MG + Liraglutide 1.8 MG was given a rating of 2 for safety based on our team's assessment at Power." - Anonymous Online Contributor

Unverified Answer

To what capacity is this investigation accommodating participants?

"At this time, recruitment for the trial is closed. The initial posting was on January 24th 2019 and the most recent update occurred in September 2020. If searching for other studies with a similar diagnosis, 2187 trials are currently recruiting patients diagnosed with type 2 diabetes, while 74 clinical trials are seeking participants to test Empagliflozin 25 MG + Liraglutide 1.8 MG as an intervention." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top